6th Commercializing Continuous Processing in Pharma Summit (CCP)

Memo

 The 6th Commercializing Continuous Processing in Pharma Summit (CCP) will reunite the continuous community to learn from early adopters on their pilot and commercial scale implementation, as Continuous finally becomes a widely adopted reality across the pharmaceutical industry. Pairing innovative case studies with regulatory perspective, pharma 4.0 technologies, and business case considerations, the CCP Summit provides a holistic playbook to taking the next step in your continuous journey across both small and large molecules.URLs:Brochure: https://go.evvnt.com/1023067-2?pid=5569Tickets: https://go.evvnt.com/1023067-3?pid=5569Prices:Pharma and Biotech Pricing - FULL PASS: Conference + Workshop + Focus Morning: USD 3997.0,Pharma and Biotech Pricing - Conference + Workshop: USD 3498.0,Pharma and Biotech Pricing - Conference + Focus Morning: USD 3498.0,Pharma and Biotech Pricing - Main Conference Only: USD 2999.0,Pharma and Biotech Pricing - Site Visit: USD 200.0,Standard Pricing - FULL PASS: Conference + Workshop + Focus Morning: USD 4197.0,Standard Pricing - Conference + Workshop: USD 3698.0,Standard Pricing - Conference + Focus Morning: USD 3698.0,Standard Pricing - Main Conference Only: USD 3199.0,Standard Pricing - Site Visit: USD 200.0Speakers: Andrew Chang, VP Quality and Regulatory Compliance, Novo Nordisk, Carla Luciani, Senior Director, Chemical Engineering Vertex Pharmaceuticals, Ganapathy Mohan, Executive Director, Merck and Co, Mark Henson, Senior Scientific Fellow and Head, Technology Excellence Takeda, Frederic Buono, Senior Associate Director, Chemical Process Development US, Boehringer Ingelheim, Paul Richardson, Director Analytical and Synthetic Technologies, Pfizer, Sarah Pope Miksinski, Senior Director, Global Regulatory Affairs, AstraZeneca, William Hein, Senior Director, Technical Operations, Small Molecule Platform, Janssen Pharmaceuticals, Alastair Florence, Director, EPSRC Future Continuous Manufacturing and Advanced Crystallisation Hub, Carolyn Cohen, Process Development Scientist, Amgen, Mark Geng, Principal Scientist, Moderna, Moiz Diwan, Head of Enabling Technologies, AbbVie, Daniel Griffin, Principal Engineer, Amgen, Martin Johnson, Senior Engineering Advisor, Process Design and Development, Eli Lilly and Company, Michel Gensini, Scientific Director and Fellow, Janssen Pharmaceuticals, Simon Hawdon, Principal Scientist , CPI Biologics, Chiali Liu, Senior Director, Process Development, Biologics CMC Teva, François Levesque, Associate Principal Scientist, Merck and Co, Larry McDermott, Process Analytics and Control Scientific Fellow, Vertex, Michael McCaman, Managing Director, BPTG BDO, Collin Morris, Principal Research Scientist, AbbVie, Eric Moschetta, Senior Scientist II, AbbVie, Nandkishor Nere, Volwiler Research Fellow/Director, AbbVie, Sarah Nielsen, Director of Protein Science, Janssen Pharmaceuticals, Bruce Parker, Associate Engineering Advisor, Eli Lilly and Co, Ernest Penachio, Vice Presentation of Technical Operations, CONTINUUS Pharmaceuticals, Irina Ramos, Director Bioprocess Technology and Engineering, AstraZeneca, Jeff Odum, CPIP Practice Leader, ATMPS and Biologics, Genesis AEC, Benjamin Rizkin, Senior Scientist, AbbVie, Jorg Sedelmeier, Platform Leader, Continuous Flow Technology, F. Hoffmann-La Roche, Oliver Steinhof, Senior scientist PAT, Biogen, Oliver Thiel, Executive Director, Process Development, Amgen, David Voigtlaender, Director, Innovation Management, Evonik, Lei Zhou, Senior Research Associate, Process Development, Moderna, Lisa Graham, Chief Operating Officer, Seeq, Michael West, Chief Technical Officer, Exopharm, Bart Rimez, Co-Owner and Technology Lead, Secoya Technologies, Hans Johansson, Global Applications Director, Purolite, Senior Representative, SK PharmtecoDate and Time: On Tuesday March 22, 2022 at 8:00 am (ends Friday March 25, 2022 at 4:00 pm)Venue Details: The Colonnade Hotel, 120 Huntington Ave, Boston, Massachusetts, 02116, United States